{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:53:00Z","timestamp":1793317980085,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.nano.2021.102506","type":"journal-article","created":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T16:31:17Z","timestamp":1638721877000},"page":"102506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus"],"prefix":"10.1016","volume":"40","author":[{"given":"Alessandra","family":"Iscaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Mughal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith Nutter","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider Al","family":"Janabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secil","family":"Demiral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Perrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Essand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Weglarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munitta","family":"Muthana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2021.102506_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA","volume":"68","author":"Bray","year":"2018","journal-title":"Cancer J Clin"},{"issue":"13","key":"10.1016\/j.nano.2021.102506_bb0010","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.omto.2019.03.008","article-title":"Oncolytic herpes simplex virus and PI3K inhibitor BKM120 synergize to promote killing of prostate cancer stem-like cells","volume":"29","author":"Wang","year":"2019","journal-title":"Mol Ther Oncolytics"},{"issue":"2","key":"10.1016\/j.nano.2021.102506_bb0015","first-page":"63","article-title":"Epidemiology of prostate cancer. World","volume":"10","author":"Prashanth","year":"2019","journal-title":"J Oncol"},{"key":"10.1016\/j.nano.2021.102506_bb0020","doi-asserted-by":"crossref","unstructured":"J. E.M. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D.M. Parkim, M. Pineros, A. Znaor, F. Bray. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144(8):1941\u20131953. hppts:\/\/doi: https:\/\/doi.org\/10.1002\/ijc.31937.","DOI":"10.1002\/ijc.31937"},{"key":"10.1016\/j.nano.2021.102506_bb0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/S0140-6736(14)61947-4","article-title":"Prostate cancer","volume":"387","author":"Attard","year":"2016","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.nano.2021.102506_bb0030","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2017.7248","article-title":"The diagnosis and treatment of prostate cancer: a review","volume":"317","author":"Litwin","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.nano.2021.102506_bb0035","first-page":"6063","article-title":"Molecular and cellular mechanisms of castration resistant prostate cancer","author":"Huang","year":"2018","journal-title":"In Oncol Lett"},{"key":"10.1016\/j.nano.2021.102506_bb0040","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.7150\/ijbs.11439","article-title":"Insights into chemoresistance of prostate cancer. In","author":"Zhang","year":"2015","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.nano.2021.102506_bb0045","first-page":"235","article-title":"Potentiating prostate cancer immunotherapy with oncolytic viruses. Nature reviews","volume":"15","author":"Lee","year":"2018","journal-title":"Urology"},{"issue":"17","key":"10.1016\/j.nano.2021.102506_bb0050","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.2174\/1381612825666190708214240","article-title":"Nanoparticles: properties and application in cancer immunotherapy","volume":"25","author":"Iscaro","year":"2019","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.nano.2021.102506_bb0055","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrclinonc.2011.72","article-title":"Immunotherapy for the treatment of prostate cancer","volume":"8","author":"Di Lorenzo","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.nano.2021.102506_bb0060","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nri2817","article-title":"Prostate cancer as a model for tumor immunotherapy","volume":"10","author":"Drake","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.nano.2021.102506_bb0065","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russel","year":"2012","journal-title":"Nat Biotechnol"},{"issue":"10","key":"10.1016\/j.nano.2021.102506_bb0070","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.nano.2021.102506_bb0075","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1089\/humc.2013.181","article-title":"Preclinical safety assessment of Ad[I\/PPT-E1A], a novel oncolytic adenovirus for prostate cancer","volume":"25","author":"Schenk","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"8","key":"10.1016\/j.nano.2021.102506_bb0080","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.nano.2021.102506_bb0085","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2217\/nnm-2019-0323","article-title":"Designer nanocarriers for navigating the systemic delivery of oncolytic viruses","volume":"15","author":"Howard","year":"2020","journal-title":"Nanomedicine (Lond)"},{"issue":"6","key":"10.1016\/j.nano.2021.102506_bb0090","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","volume":"3","author":"Lawler","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.nano.2021.102506_bb0095","first-page":"4968","article-title":"Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer","volume":"62","author":"Freytag","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.nano.2021.102506_bb0100","first-page":"884","article-title":"Past, current, and future of immunotherapies for prostate cancer. Front","volume":"9","author":"Boettcher","year":"2019","journal-title":"Oncologia"},{"key":"10.1016\/j.nano.2021.102506_bb0105","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/mt.sj.6300120","article-title":"Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer","volume":"15","author":"Freytag","year":"2007","journal-title":"Mol Ther"},{"issue":"14","key":"10.1016\/j.nano.2021.102506_bb0110","doi-asserted-by":"crossref","first-page":"261","DOI":"10.21037\/atm.2016.04.01","article-title":"Harnessing the immune system to improve cancer therapy","volume":"4","author":"Papaioannou","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.nano.2021.102506_bb0115","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14:73","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.nano.2021.102506_bb0120","doi-asserted-by":"crossref","unstructured":"Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011;11:723\u201337. 10.1038\/nri3073.","DOI":"10.1038\/nri3073"},{"key":"10.1016\/j.nano.2021.102506_bb0125","doi-asserted-by":"crossref","unstructured":"Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, Kaiser EA, Snyder LA, Pollard JW. CCL2 recruits inflammatory monocytes to facilitate breast-tumor metastasis. Nature 2011;475:222\u20135. 10.1038\/nature10138.","DOI":"10.1038\/nature10138"},{"key":"10.1016\/j.nano.2021.102506_bb0130","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/sj.bjc.6690158","article-title":"Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast","volume":"79","author":"Leek","year":"1999","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nano.2021.102506_bb0135","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S0002-9440(10)63483-9","article-title":"Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy","volume":"163","author":"Burke","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.nano.2021.102506_bb0140","doi-asserted-by":"crossref","unstructured":"M. Muthana, A. Giannoudis, S.D. Scott, H.Y. Fang, S.B. Coffelt, F.J. Morrow et al. Use of macrophages to target therapeutic adenovirus to human prostate tumors. Cancer Res. 2011;71(5):1805\u201315. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2349. Ex 25","DOI":"10.1158\/0008-5472.CAN-10-2349"},{"issue":"2","key":"10.1016\/j.nano.2021.102506_bb0145","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/0008-5472.CAN-12-3056","article-title":"Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation","volume":"73","author":"Muthana","year":"2013","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.nano.2021.102506_bb0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.cgt.7700881","article-title":"An oncolytic conditionally replicating adenovirus for hormone-dependent and hormone-independent prostate cancer","volume":"13","author":"Cheng","year":"2006","journal-title":"Cancer Gene Ther"},{"issue":"130","key":"10.1016\/j.nano.2021.102506_bb0165","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"4","author":"Martinez-Quintanilla","year":"2019","journal-title":"J Clin Invest"},{"issue":"17","key":"10.1016\/j.nano.2021.102506_bb0170","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1158\/0008-5472.CAN-14-3587","article-title":"Perivascular M2 macrophages stimulate tumor relapse after chemotherapy","volume":"75","author":"Hughes","year":"2015","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.nano.2021.102506_bb0175","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2217\/nnm.16.5","article-title":"The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction","volume":"11","author":"Hoshyar","year":"2016","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.nano.2021.102506_bb0180","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/727241","article-title":"Targeted liposomal drug delivery to monocytes and macrophages","volume":"2011","author":"Kelly","year":"2011","journal-title":"J Drug Deliv"},{"key":"10.1016\/j.nano.2021.102506_bb0190","first-page":"79","article-title":"Regulation of T-cell activation","volume":"111","author":"Gajewskj","year":"1989","journal-title":"Differences among T-cell subsets. Immunol Rev"},{"issue":"11","key":"10.1016\/j.nano.2021.102506_bb0195","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41577-018-0056-9","article-title":"Perivascular macrophages in health and disease","volume":"18","author":"Lapenna","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.nano.2021.102506_bb0200","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ccell.2016.05.017","article-title":"The multifaceted role of perivascular macrophages in tumors","volume":"30","author":"Lewis","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.nano.2021.102506_bb0205","doi-asserted-by":"crossref","unstructured":"Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JM, Papaemmanuil E, Brewer DS, Kallio HM, H\u00f6gn\u00e4s G, Annala M, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015; 520:353\u2013357. 10.1038\/nature14347.","DOI":"10.1038\/nature14347"},{"issue":"19","key":"10.1016\/j.nano.2021.102506_bb0210","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.2217\/nnm-2017-0208","article-title":"Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics","volume":"12","author":"Grimaldi","year":"2017","journal-title":"Nanomedicine (Lond)"},{"issue":"5","key":"10.1016\/j.nano.2021.102506_bb0215","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1734-1140(12)70901-5","article-title":"Nanoparticles as drug delivery systems","volume":"64","author":"Wilczewska","year":"2012","journal-title":"Pharmacol Rep"},{"issue":"12","key":"10.1016\/j.nano.2021.102506_bb0220","doi-asserted-by":"crossref","first-page":"11548","DOI":"10.1021\/acsnano.6b06182","article-title":"Oncolytic adenovirus complexes coated with lipids and calcium phosphate for cancer gene therapy","volume":"10","author":"Chen","year":"2016","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.nano.2021.102506_bb0225","doi-asserted-by":"crossref","first-page":"14177","DOI":"10.1038\/s41598-017-14717-x","article-title":"Liposome-encapsulated plasmid DNA of telomerase-specific oncolytic adenovirus with stealth effect on the immune system","volume":"7","author":"Aoyama","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.nano.2021.102506_bb0230","doi-asserted-by":"crossref","unstructured":"G. Bozzuto, A. Molinari. Liposomes as nanomedical devices. Int J Nanomedicine 2015;10:975\u201399. 10.2147\/IJN.S68861.","DOI":"10.2147\/IJN.S68861"},{"issue":"2","key":"10.1016\/j.nano.2021.102506_bb0235","article-title":"Liposomal formulations in clinical use","volume":"9","author":"Bulbake","year":"2017","journal-title":"an updated review. Pharmaceutics"},{"issue":"10","key":"10.1016\/j.nano.2021.102506_bb0240","doi-asserted-by":"crossref","first-page":"861","DOI":"10.2174\/1567201817666200708113131","article-title":"Liposomes for enhanced cellular uptake of anticancer agents","volume":"17","author":"El Maghraby","year":"2020","journal-title":"Curr Drug Deliv"},{"key":"10.1016\/j.nano.2021.102506_bb0245","doi-asserted-by":"crossref","unstructured":"Henriksen-Lacey M., Bramwell VW., Christensen D. et al. Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen. J Control Release 2010 Mar 3;142(2):180\u20136. https:\/\/doi.org\/10.1016\/j.jconrel.2009.10.022. Epub 2009 Oct 26. PMID: 19874860","DOI":"10.1016\/j.jconrel.2009.10.022"},{"issue":"1","key":"10.1016\/j.nano.2021.102506_bb0250","first-page":"710 724","article-title":"PEGylated liposomes: immunological responses","volume":"20","author":"Marwa","year":"2019","journal-title":"Science and Technology of Advanced Materials"},{"issue":"3","key":"10.1016\/j.nano.2021.102506_bb0255","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1002\/jcb.21220","article-title":"CCR2 expression correlates with prostate cancer progression","volume":"101","author":"Lu","year":"2007","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.nano.2021.102506_bb0260","doi-asserted-by":"crossref","unstructured":"L. Zhang, F. Hedjran, C. Larson et al. A novel immunocompetent murine model for replicating oncolytic adenoviral therapy. Cancer Gene Ther 22, 17\u201322 (2015). https:\/\/doi.org\/10.1038\/cgt.2014.64.","DOI":"10.1038\/cgt.2014.64"},{"key":"10.1016\/j.nano.2021.102506_bb0265","doi-asserted-by":"crossref","unstructured":"S.J. Duncan, F.C. Gordon, D.W. Gregory, J.L. McPhie, R. Postlethwaite, R. White et al. Infection of mouse liver by human adenovirus type 5. J Gen Virol 1978; 40: 45\u201361. Return to ref 4 in article. CASArticle Google Scholar","DOI":"10.1099\/0022-1317-40-1-45"},{"key":"10.1016\/j.nano.2021.102506_bb0270","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1073\/pnas.88.5.1651","article-title":"A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia","volume":"88","author":"Ginsberg","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2021.102506_bb0275","doi-asserted-by":"crossref","unstructured":"S.I. Grivennikov, F.R. Greten, M. Karin. Immunity: \u201cinflammation, and cancer\u201d. Cell 2010; 140, 883\u2013899. https:\/\/doi.org\/10.1016\/j.cell.2010.01.025.","DOI":"10.1016\/j.cell.2010.01.025"},{"key":"10.1016\/j.nano.2021.102506_bb0280","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.nano.2021.102506_bb0285","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.nano.2021.102506_bb0290","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","article-title":"The three Es of Cancer immunoediting","volume":"22","author":"Dunn","year":"2004","journal-title":"Annu Rev Immunol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963421001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:18:39Z","timestamp":1761549519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963421001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":55,"alternative-id":["S1549963421001490"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2021.102506","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting circulating monocytes with CCL2-loaded liposomes armed with an oncolytic adenovirus","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2021.102506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102506"}}